Who
Sanjeev Narula
Chief Financial & Bus. Officer
Company insider
Files Form 4 as: Chief Financial & Bus. Officer, Phathom Pharmaceuticals; Executive Vice President & CFO, Intra-Cellular Therapies; Chief Financial Officer, Viatris.
In numbers
- Trades disclosed
- 49
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 20 Nov 2020
- Last trade
- 6 Oct 2026
- Last filed
- 8 Oct 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 8 Oct 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $91K13,485 at $6.78 | filing |
| 2 Jan 2026filed 2 Jan 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —82,715 at $0.00 | filing |
| 2 Jan 2026filed 2 Jan 2026 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,848 at $0.00 | filing |
| 2 Jan 2026filed 2 Jan 2026 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,848 at $0.00 | filing |
| 2 Jan 2026filed 2 Jan 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —82,715 at $0.00 | filing |
| 6 Oct 2025filed 8 Oct 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —144,000 at $0.00 | filing |
| 6 Oct 2025filed 7 Oct 2025 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —17,251 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —35,046 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —22,727 | filing |
| 3 Feb 2025filed 4 Feb 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code A | —22,727 at $0.00 | filing |
| 12 Aug 2024filed 14 Aug 2024 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code A | —17,251 at $0.00 | filing |
| 12 Aug 2024filed 14 Aug 2024 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code A | —35,046 at $0.00 | filing |
| 4 Mar 2023filed 6 Mar 2023 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —38,889 at $0.00 | filing |
| 4 Mar 2023filed 6 Mar 2023 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,397.79 at $0.00 | filing |
| 4 Mar 2023filed 6 Mar 2023 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —38,889 at $0.00 | filing |
| 4 Mar 2023filed 6 Mar 2023 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code F | $188K16,909 at $11.13 | filing |
| 4 Mar 2023filed 6 Mar 2023 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —1,398 at $0.00 | filing |
| 4 Mar 2023filed 6 Mar 2023 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code F | $6,767608 at $11.13 | filing |
| 3 Mar 2023filed 6 Mar 2023 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —116,353 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.